Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CnU Cap. 500 mg in Patients With Biliary Dyspepsia
NCT07016269Phase 4Recruiting
- Sponsor
- Myungmoon Pharm
- Start
- Aug 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of CnU, sponsored by Myungmoon Pharm. Started Aug 2025; status: recruiting.
02
Drugs
CnU
Beyond the preview
Go deeper on NCT07016269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07016269.